Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
2021 · Amyloid · 103 citations
https://doi.org/10.1080/13506129.2021.2002841
H
Heather Landau
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
515
Papers
7.9K
Citations
44
h-index
128
i10-index
Heather Landau is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Amyloidosis: Diagnosis, Treatment, Outcomes & Protein Degradation and Inhibitors. The author has an h-index of 44, co-authored 438 publications.
ORCID: 0000-0002-3152-1189Papers by this author
worksLight chain (AL) amyloidosis: update on diagnosis and management
2011 · Journal of Hematology & Oncology · 82 citations
https://doi.org/10.1186/1756-8722-4-47
Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study
2020 · Blood · 78 citations
https://doi.org/10.1182/blood.2020006923
Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis
2020 · JACC CardioOncology · 59 citations
https://doi.org/10.1016/j.jaccao.2020.05.012
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
2016 · Leukemia · 55 citations
https://doi.org/10.1038/leu.2016.229
Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)
2019 · Blood · 39 citations
https://doi.org/10.1182/blood-2019-124409
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat